Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up – Time to Buy?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s share price gapped up before the market opened on Thursday. The stock had previously closed at $41.08, but opened at $44.24. Supernus Pharmaceuticals shares last traded at $43.41, with a volume of 75,670 shares changing hands.

More Supernus Pharmaceuticals News

Here are the key news stories impacting Supernus Pharmaceuticals this week:

• Positive Sentiment: Supernus raised its full-year 2026 earnings guidance, strengthening the outlook for profitability and serving as the primary positive catalyst for SUPN. Supernus Raises 2026 Earnings Guidance
• Positive Sentiment: The company reported third-quarter adjusted earnings of $0.93 per share, exceeding the $0.49 consensus estimate. Revenue also reportedly surpassed expectations in the company’s earnings release coverage, supporting the view that operating performance remains solid. Supernus Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Management described the full-year sales outlook as optimistic, while the earnings call offered additional detail on the company’s commercial performance and 2026 expectations. Supernus Delivers Strong Q3 and Optimistic Sales Guidance
• Neutral Sentiment: Reported figures vary depending on the accounting measure: one summary cited GAAP EPS of $0.35 and revenue of $208.6 million, below consensus, while adjusted EPS was $0.93. Investors are likely focusing on the adjusted results and upgraded guidance, but the GAAP shortfall remains a consideration. Supernus Third-Quarter 2026 Financial Results

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on SUPN shares. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Cantor Fitzgerald boosted their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Weiss Ratings cut Supernus Pharmaceuticals from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Friday. Finally, Zacks Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, October 5th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Reduce” and a consensus target price of $62.33.

Supernus Pharmaceuticals Stock Up 0.2%

The business has a 50-day simple moving average of $42.50 and a two-hundred day simple moving average of $47.32. The stock has a market capitalization of $2.44 billion, a P/E ratio of -54.44, a PEG ratio of 1.23 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.49 by ($0.14). Supernus Pharmaceuticals had a negative net margin of 5.07% and a positive return on equity of 13.01%. The company had revenue of $208.60 million for the quarter, compared to the consensus estimate of $217.56 million. During the same period in the previous year, the business posted ($0.80) earnings per share. The firm’s revenue was up 18.0% compared to the same quarter last year. On average, sell-side analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.79 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new stake in Supernus Pharmaceuticals during the 2nd quarter worth about $434,871,000. Bank of America Corp DE lifted its position in Supernus Pharmaceuticals by 37.2% during the 1st quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock valued at $36,918,000 after purchasing an additional 193,479 shares during the period. Ashford Capital Management Inc. boosted its stake in shares of Supernus Pharmaceuticals by 5.4% in the 1st quarter. Ashford Capital Management Inc. now owns 645,381 shares of the specialty pharmaceutical company’s stock valued at $33,360,000 after purchasing an additional 32,843 shares during the last quarter. Rice Hall James & Associates LLC boosted its stake in shares of Supernus Pharmaceuticals by 2.0% in the 1st quarter. Rice Hall James & Associates LLC now owns 477,416 shares of the specialty pharmaceutical company’s stock valued at $24,678,000 after purchasing an additional 9,530 shares during the last quarter. Finally, Systematic Financial Management LP grew its position in shares of Supernus Pharmaceuticals by 23.6% during the 1st quarter. Systematic Financial Management LP now owns 376,079 shares of the specialty pharmaceutical company’s stock worth $19,440,000 after buying an additional 71,853 shares during the period.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company’s activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus’ marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.